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Summary
Asthma is the most frequently encountered allergic respiratory disease, and one that has
a potentially serious impact on patients’ functioning and well-being. From a public health
perspective, it is important to collect data on the prevalence, burden and management of
asthma in order to improve understanding of the pathogenesis of asthma and to ensure that
national healthcare policies are adapted and appropriate. In this respect, the different AIR
surveys, which have collected standardised data on asthma in the general population of
a large number of countries around the world, have made an important contribution. The
latest of these surveys is the AIRMAG survey, performed in the three Maghreb countries of
Algeria, Morocco and Tunisia. In these countries, the prevalence of asthma (3.4% to 3.9%) is
in the low to moderate range. This is consistent with rates observed elsewhere in the Med-
iterranean basin. Nonetheless, the prevalence of asthma in the Maghreb may be expected
to rise in the future as populations become more urbanised and adopt a more ‘Westernised’
lifestyle. Indeed the prevalence of asthma is already higher in the urban coastal regions
of these countries than in the more rural mountainous and desert regions. Asthma control
in the Maghreb is relatively poor compared to other regions evaluated in previous AIR
studies, with control being unacceptable in around three-quarters of respondents. Although
part of the explanation may reside in limited access to care, treatment rates for inhaled
corticosteroids (26.1% of adults and 29.1% of children) were no worse than those reported
in previous AIR studies. On the other hand, asthma monitoring through regular follow-up
visits, home ﬂow-meter use and preparation of individualised asthma management plans
was in general unsatisfactory. In addition, awareness of asthma in the general population
of the Maghreb countries was low. Education measures directed at the patient, together
with programmes directed at the physician to ensure systematic monitoring and the use
of a ’treat to target’ approach to therapy, could do much to increase quality of life and
minimise restrictions on activities in patients with asthma in the Maghreb.
© 2009 Published by Elsevier Ltd.
Asthma is a chronic respiratory disease affecting around
300 million people worldwide, and this number is rising
due to demographic growth and to lifestyle changes 1.
Although asthma affects individuals in all countries, of all
ages and of all ethnic groups, prevalence rates for clinical
asthma (which have been reported to vary from around
1% in Indonesia to around 18% in Scotland 1), management
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paradigms, the severity and control of asthma may differ
markedly between countries.
In order to understand these geographical differences,
and to help adapt public health policies for asthma
management to local needs, information on asthma needs
to be collected in a standardised way worldwide. A
number of multinational epidemiological studies have been
performed with the aim of comparing the burden of asthma
between countries. Two of these, both performed in the
early nineties, have been particularly informative due
to their extensive geographical coverage and the large
numbers of individuals included. These are the European
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Table 1. Regional and national surveys using the AIR methodology
Survey Region Year Participating countries N
Households Asthma
AIA 14,15 North America 1998 United States 42,022 2,509
AIRC 16 North America 1999 Canada 49,767 1,001
AIRE 17 Europe 1999 France, Germany, Italy, The Netherlands, Spain, Sweden, UK 73,880 2,803
AIRIAP 18 Asia-Paciﬁc 2000 China, Hong Kong, Korea, Malaysia, Philippines, Singapore, Taiwan, Vietnam 108,360 3,207
AIRJ [19 21] Asia-Paciﬁc 2000,2005 Japan 38,132 a 803 a
AIRCEE 19 Eastern Europe 2001 Bulgaria, Croatia, Czech Republic, Hungary, Latvia, Lithuania, Poland,
Romania, Russia, Slovakia, Slovenia, Ukraine
NAb 1,617
AIRLA 20 Latin America 2003 Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Paraguay,
Peru, Uruguay, Venezuela
46,275 2,184
AMOA21 Australasia 2003 Australia 42,837 1,205
AIRET 22 Middle East NA Turkey 8,350 400
AIRGNE 23 Middle East 2007 Jordan, Kuwait, Lebanon, Oman, United Arab Emirates QMc 1000
AIRSA 24 Middle East 2007 Saudi-Arabia QMc 700
AIRNZ d Australasia NA New Zealand NA NA
AIRMAG North Africa 2008 Algeria, Morocco, Tunisia 46,989 872
a These ﬁgures correspond to the ﬁrst (2000) AIRJ survey.
b No information on the number of households contacted is available for the AIRCEE survey, nor on the prevalence rates observed.
c The AIRGNE and AIRSA surveys used a quota method with a target number of individuals with asthma to recruit. This selection method precluded the
determination of asthma prevalence in these two studies.
d No published data is available for the AIRNZ survey.
Community Respiratory Health Survey (ECRHS) 2, which
addressed asthma in young adults (20 44 years old), and
the International Survey of Asthma and Allergy in Children
(ISAAC) 3,4, which investigated paediatric asthma.
The ECRHS was funded by the European Commission
and initiated in 1990. It evaluated prevalence of asthma
symptoms, risk factors, airway responsiveness and use of
health services in interviewees from selected regions of
seventeen European countries, later extended to ﬁve non-
European countries (Algeria, Australia, India, New Zealand
and the USA). The prevalence of asthma symptoms was
found to be generally lower in Mediterranean countries
than in the British Isles, New Zealand, Australia and the
United States. In the ISAAC study, schoolchildren in two
discrete age groups (6 7 year-olds and 13 14 year-olds)
in speciﬁed geographical areas were asked about asthma
using a written and video questionnaire. Fifty-six countries
from all continents participated and provided the ﬁrst world
map of the prevalence of paediatric asthma. Again, striking
regional differences in the prevalence of asthma symptoms
were noted, the prevalence of wheezing, for example,
being less than ﬁve percent in most Asian countries and
over thirty percent in the United Kingdom were noted.
However, both these surveys present certain limitations.
These relate to the restricted age groups considered, and
the geographical areas of each country investigated, which
were not randomly selected and generated a number of
unanticipated within-country disparities in prevalence.
There is also information suggesting that the prevalence
of asthma may be increasing over time 5,6. This has come
from several national studies comparing the prevalence
of asthma in the same target population at two different
time points, for example surveys performed in the USA 7,
Australia 8 the Netherlands 9 and Scotland 10. Similarly, a
reiteration of the ISAAC study, conducted in 2002 2003 in
many of the same centres as the original survey, reported
rises in the prevalence of asthma in many countries
studied 11. In the ECRHS survey a strong association was seen
between birth cohort and incidence of asthma, this being
higher in individuals born later on 12. However, a reiteration
of the ECHRS 13, in which the same patients from the
ﬁrst survey were interviewed again in 1998 2003, showed
no increase in the prevalence of symptoms, although the
proportion of interviewees reporting having received a
diagnosis of asthma had increased.
The Global Initiative for Asthma (GINA) was established
in 1993 by the World Health Organization with the goals of,
inter alia, increasing awareness of asthma and its public
health consequences, and of improving the management of
asthma and the availability and accessibility of effective
asthma therapies. Since that time, GINA has played an
important role in collecting, collating and making available
data on asthma collected around the world and in providing
guidelines for optimising the management of asthma by
physicians.
Subsequently, the Asthma Insights and Reality (AIR)
programme has been initiated with the aim of collecting
epidemiological data on asthma control and management
from the patient’s perspective, and of determining to
what extent the treatment goals of the GINA guidelines
are being met. This programme was initiated and funded
by GlaxoSmithKline laboratories, who have a longstanding
involvement in the treatment of asthma.
The AIR surveys
The AIR surveys use a standardised, computer-assisted
telephone interview method to collect data on asthma from
a randomly selected sample of the general population,
and thus should generate a reliable national prevalence
estimate for asthma. As well as collecting data on
prevalence and severity of asthma, the AIR surveys also
investigate asthma control, the burden of asthma, the
management and treatment, and the perceptions and
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Fig. 1. Prevalence rates reported in the different AIR surveys. For most surveys, a nationwide population was evaluated. In the AIRAP survey (Asia-
Paciﬁc), only metropolitan centres were considered. These are indicated on the map as coloured spots In the AIRLA (Latin America) and AIRET (Turkey),
only urban centres were considered, but these are not speciﬁed in the source publications. Prevalence data are not available for the AIRCEE, AIRGNE,
AIRSA and AIRNZ surveys.
understanding of asthma. The AIR surveys have now been
performed in eight regions of the world, starting with North
America in 1998, and have collectively interviewed nearly
half a million people (Table 1). The most recent contribution
to the AIR programme has come from the AIRMAG survey,
performed in three Maghreb countries (Algeria, Morocco and
Tunisia). The ﬁndings of the AIRMAG survey are described in
detail in this supplement.
Asthma prevalence
The data collected in the various AIR surveys have revealed
major differences in asthma prevalence rates between
countries (Fig. 1). These geographical differences are
broadly consistent with those reported for children in the
earlier ISAAC surveys. The prevalence rates estimated for
the Maghreb countries (3.4% in Algeria, 3.5% in Tunisia and
3.9% in Morocco) are higher than those reported in most
Latin American countries, most Asian countries, Japan and
Germany, but lower than those reported for the Philippines,
Uruguay, most Western European countries, Taiwan, Turkey,
Costa Rica, Venezuela, Korea, the United States, and above
all, Australia and Singapore. The prevalence of asthma was
somewhat higher in children than in adults, as in the other
AIR surveys, although this difference was not major (crude
prevalence in adults: 3.5; in children: 4.0%).
The prevalence rates observed in the AIRMAG survey 25
can perhaps best be compared with those from AIRET
in Turkey 22, with which the Maghreb countries share a
common Mediterranean lifestyle and Islamic culture. Given
that the AIRET study was only carried out in urban centres,
the prevalence rates observed are quite similar. It should
nonetheless be pointed out that, paradoxically, the recent
PARFAIT study of allergic diseases in Turkey 26 reported
that the prevalence of childhood asthma was higher in
rural than in urban centres, a ﬁnding that is inconsistent
with the results of the AIRMAG study 25 and numerous
other studies performed elsewhere in Africa 27 and other
developing countries 28.
The ﬁfteen-fold variation in the prevalence of asthma
between different regions of the world observed in the
AIR studies is largely consistent with the ﬁndings of the
ISAAC study a decade previously 4. It is interesting to
speculate why such differences may arise. As a general rule,
prevalence seems to be relatively high in the British Isles,
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North America and Australasia and relatively low in most
developing countries. Although genetic differences cannot
be excluded, as suggested by the important hereditary
component to asthma, the genetics of asthma are complex
and poorly understood 29,30. It seems unlikely that any single
gene plays a major role in the predisposition for asthma,
and multiple genetic factors may inﬂuence susceptibility to
environmental risk factors for asthma rather than playing a
direct role in pathogenesis. In the second National Health
and Nutrition Examination Survey (NHANES II) performed
in the USA, the prevalence of asthma was signiﬁcantly
higher in individuals of Caucasian origin (9.2%) compared to
Afro-Americans (6.9%) 31, although this difference could be
explained by socioeconomic factors as well as by ethnicity.
Indeed, such a difference was no longer observed ten
years later at the time of the third NHANES survey 32. A
preponderant inﬂuence of environmental factors thus seems
likely, which has been suggested by a number of studies
investigating immigrant communities. For example, a study
of Turkish children in Germany 33 showed that a higher
degree of cultural adaptation was associated with a higher
prevalence of atopy and asthma. Data from the ECRHS
study indicate that migrants generally acquire the asthma
prevalence status of their host countries 34. Similarly, in
the NHANES III study in the USA, the prevalence of asthma
was higher in Mexican-Americans born and raised in the
USA than in immigrants from Mexico 35. An adoption study
in Sweden 36 has shown that the earlier children adopted
from developing countries arrived in Sweden, the more
likely they were to develop asthma. On the other hand,
another study by the same group 37 revealed that children
born in Sweden to immigrants retain a similar relative
risk of developing asthma to their parents, suggesting that
ethnicity plays some role.
Generally speaking, it appears that countries and
populations with a higher standard of living, that are more
urbanised, and have a more ‘westernised’ lifestyle present
higher prevalence rates for asthma. A striking example of
this comes from a series of studies in Germany, where
asthma prevalence in the former East Germany, which
was previously half that in West Germany 38, has risen to
Western rates in children born since reuniﬁcation 39. In the
ISAAC study, a strong correlation was observed between the
prevalence of asthma attributable to atopy (but not non-
atopic asthma) and national per capita income 40. On the
other hand, within countries, high asthma risk is associated
with low economic status, for example as observed in the
NHANES III survey 32 and more recently in the Portugal
Health Survey 41, and with poor housing conditions 42.
Various factors have been suggested to explain these
ﬁndings, including exposure to an agricultural environment,
which may offer protection against developing asthma,
exposure to airborne or industrial pollutants, which would
increase risk, and dietary factors 27,28,43. A number of
studies, including the ECRHS, have shown that children
growing up on farms have a lower risk of asthma than
others 44 46. For example, in the ALEX study, it has been
postulated that allergens encountered in early life may
inhibit polarisation of helper T cell development towards
a Th2 phenotype 47,48, which is thought to underlie atopic
sensitisation 49. In addition, a study in France reported
a lower prevalence of asthma in children living in a
mountainous area, related to lower exposure to house dust
mite allergens with altitude 50. The AIRMAG study, which
demonstrated two- to three-fold differences in prevalence
between rural and urban regions of the Maghreb 25 is
consistent with such observations. Although air pollution is
clearly detrimental to respiratory function, it is unlikely
that this can explain the regional differences in asthma
prevalence, since studies from Germany 38 and China 43 have
indicated that asthma is less frequent in highly polluted
industrial areas than in wealthier regions with an economy
based on the tertiary sector. Similarly, smoking rates, and
thus exposure to tobacco smoke, is high in many developing
countries, including Tunisia in the Maghreb, although
asthma prevalence rates are low. It thus seems that any
deleterious effect of airborne pollution is overridden by a
protective effect of a less ‘Westernised’ society.
It is also possible that tuberculosis or other respiratory
infections that are relatively frequent in the Maghreb
confer some degree of protection against asthma. For
example, in the ISAAC survey, tuberculosis notiﬁcation
rates between participating countries were negatively
associated with asthma prevalence rates 51. According to
recent WHO data 52, the incidence of tuberculosis in the
Maghreb countries range from 25 cases in Tunisia to
93 cases in Morocco per 100,000 individuals per year,
compared to incidence rates of less than twenty in most
Western European countries, North America and Japan 52.
In addition, a number of studies have shown neonatal anti-
tubercular BCG vaccination to be associated with a reduced
risk of subsequent development of asthma in children 53 55.
Moreover, a Korean study showed that BCG vaccination
in active asthma patients led to an amelioration in
symptoms 56, perhaps through modiﬁcation of the Th1/Th2
balance in the T helper cell population. In contrast,
infections with certain viruses that target the respiratory
tract, such as respiratory syncytial virus, inﬂuenza virus
and rhinovirus, as well as bacterial infections with
Mycoplasma pneumoniae and Chlamydophila pneumoniae,
may increase the risk of developing asthma or predispose
to exacerbations 57,58. It is possible that differences in
the occurrence of these infections between regions may
contribute to the variation in asthma prevalence observed
worldwide.
Finally, diet has been suggested to contribute to regional
differences in asthma prevalence, and also to the increase
in prevalence observed over time in many countries 59 61.
In the ISAAC cohort, an inverse relationship between
national fruit and vegetable consumption patterns and
asthma prevalence has been described 62, and a number
of studies have suggested a protective effect of a
‘Mediterranean’ diet against the development of asthma
and other atopic diseases 63. In this respect, the patterns
of asthma prevalence observed in the different AIR studies
would be consistent with this hypothesis, with relatively low
prevalence rates (<5%) being observed in all the Maghreb
countries 25, as well as in Italy and Spain 17. An association
between asthma and obesity has been observed in many
countries and it has been suggested that excessive weight
is a risk factor for the development of asthma 64.
Although historically low, as elsewhere in the Arab-
speaking world, the prevalence of obesity in the Maghreb
countries has risen dramatically over the last two
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decades 65, due to increased sedenterisation and changes
in diet, and now is approaching prevalence rates seen
in industrialised countries. It may thus be anticipated
that the increases in obesity and generally increasingly
‘westernised’ life style occurring in the Maghreb may
bring with it a rise in the prevalence of asthma, and
it will be important to follow any emerging trends
carefully so that public health policies can be adapted
accordingly. The data collected in the AIRMAG survey
reported in this supplement will serve as an important
reference source to monitor any future changes in the
prevalence of asthma in the Maghreb due to lifestyle
changes or changes in the burden of disease brought
about by the implementation of public health policies
aimed at improving standards of care. In addition,
the AIR methodology provides a sufﬁciently sensitive
instrument to detect changes in the experience of
asthma in general population samples, as witnessed by
the two consecutive AIR studies performed in Japan in
2000 and 2005 66,67.
Asthma control
A number of the AIR studies, particularly the earlier
ones, evaluated the severity of asthma according to a
classiﬁcation proposed by GINA in its earlier releases
on the basis of the frequency of nocturnal and diurnal
symptoms, of exercise-induce symptoms and of severe
asthma episodes. However, this evaluation does not take
into account any treatment the patient may be taking,
which may confound the evaluation in the case of effective
treatment control. In the majority of these studies, the
distribution of severity grades was rather similar, with
around half of the subjects being classiﬁed as intermittent
and around 20% as severe persistent. The two exceptions
to this rule are the AIRCEE study in Central and Eastern
Europe and the AIRMAG study (Table 2), in which the
severity distribution of the samples was shifted towards
higher severity. The reason for this difference is not clear,
since an identical questionnaire was used in all studies.
However, these data on severity are difﬁcult to interpret,
particularly in an age in which most patients whose
underlying disease is severe are, or should be, receiving an
appropriate treatment. Thus, an individual could be classed
in the ‘intermittent’ category either because the underlying
Table 2. Asthma severity classiﬁcation in different AIR surveys a
Survey Intermittent Persistent
Mild Moderate Severe
Asthma in America 14,15 43% 16% 22% 19%
AIRE 17 44% 19% 19% 18%
AIRIAP 18 53% 20% 16% 11%
AIRJ 68 54% 12% 19% 15%
AIRCEE 19 22% 19% 27% 32%
AIRLA 20 47% 22% 10% 22%
AIRMAG
Adults
Children
23.5%
30.9%
24.8%
27.6%
17.3%
18.7%
34.5%
22.8%
a Asthma severity was calculated using the same GINA-based algorithm in
all surveys 19. Data from surveys other than AIRMAG are taken from Rabe
et al., 2004 19.
disease was not severe or because it is was in fact severe
but the treatment offered was sufﬁciently effective to
control the symptoms adequately. It is thus important to
distinguish between the concept of asthma control and that
of asthma severity, the former being more relevant from a
management point of view. The American Thoracic Society
has recently proposed operational deﬁnitions of these
two aspects, which clarify this distinction well 69. Asthma
control is deﬁned as ‘the extent to which the various
manifestations of asthma have been reduced or removed
by treatment’ and asthma severity as ‘the difﬁculty in
controlling asthma with treatment’. Severity can thus be
considered as the therapeutic pressure required to obtain
and maintain satisfactory asthma control. From a treatment
perspective, it is important to ascertain the degree of
asthma control since the recommended management of
asthma involves a ‘treat to target’ approach in which the
intensity of treatment is adjusted to achieve and then
maintain optimal asthma control.
In the AIR studies, different approaches to the measure of
asthma control have been adopted. The most simple, used
for example in the AMOA study in Australia, was to ask par-
ticipants how well they thought that their asthma had been
controlled, without specifying what was meant by ‘control’.
In most of the studies, a composite measure of control
was generated from answers to explicit questions on the
ﬁve symptom-related criteria for control proposed by GINA,
originally put forward in the ﬁrst set of guidelines issued
in 1995, and retained and reﬁned in subsequent versions of
these guidelines. The sixth criterion, relating to pulmonary
function, cannot be assessed by telephone interview. These
ﬁve criteria are the absence of daytime symptoms (no more
than twice a week), the absence of night-time symptoms,
no limitations in activities, no need for rescue medication
(no more than twice a week) and no exacerbations. The
third, and most sophisticated, approach was to use a
validated speciﬁc patient-reported outcome measure to
estimate control. This was the approach adopted in the
AIRET 70 AIRSA 24 and AIRGNE 23 studies in the Middle-East.
All three methods were applied in the AIRMAG study.
For those studies that assessed control through questions
related to the GINA criteria, the response rates for each
question obtained in the different surveys are presented
in Table 3. In general, asthma control appeared to be
better in the USA, Japan and Western Europe than in
the countries covered by the others surveys. In particular,
performance on the items related to lung function testing
was worst in the AIRMAG survey. The AIRSA survey reported
the highest rate of emergency department visits (Fig. 2)
and the highest proportion of subjects with daytime and
nighttime symptoms. The proportion of AIRMAG respondents
who fulﬁlled all the GINA control criteria was very low, 7.6%.
This is consistent with similarly poor overall control rates
described in other AIR surveys, for example 5.3% in AIRE,
2.4% in AIRLA and 1.25% in AIRET.
For the studies using a speciﬁc patient-reported outcome
measure (AIRET, AIRGNE, AIRSA and AIRMAG), the Asthma
Control Test (ACT) was used. For this instrument, a score of
20 or more corresponds to well-controlled asthma. Using the
ACT, the level of control observed in the AIRMAG study, in
which 28.7% scored at least twenty on this scale appeared
somewhat better than that reported previously in Turkey
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Table 3. Asthma control estimated from replies to questions related to the GINA control criteria in different AIR studies a
GINA guideline goal
AIR survey item
AIA
1998
AIRE
1999
AIRIAP
2000
AIRJ
2000
AIRCEE
2001
AIRSA
2008
AIRGNE
2008
AIRMAG
2008
Minimal chronic symptoms
Daytime symptoms in last four weeks
Night-time awakenings in last four weeks
Sleep disruption more than once a week
61%
41%
30%
56%
36%
30%
51%
44%
28%
51%
41%
20%
74%
59%
51%
75%
69%
42%
68%
51%
42%
70.1%
67.8%
47.4%
Minimal exacerbations
Hospital admission in last year
Emergency department visit in last year
9%
23%
7%
10%
15%
19%
10%
13%
19.1%
20.7%
24%
70%
23%
52%
12.1%
26.9%
Minimal need for SABA
Current use of bronchodilator 61% 63% 56.3% 39% 54.3% 82% 56% 59.7%
No limitation on physical activity
Asthma restricts normal physical activity 36% 32% 45% 17% 68.2% 57% 48% 32.0%
(Near) Normal lung function
Lung function never tested
Lung function tested in the last year
Owns a peak ﬂow meter
Regularly uses a peak ﬂow meter
53.2%
35%
28%
8.4%
53.7%
33%
28%
8%
60%
33%
7%
3%
68%
29%
9%
4%
36.2%
52.2%
5.6%
2.8%
NA
23%
18%
NA
66%
32.7%
17.1%
NA
83.0%
14.0%
4.5%
2.8%
a SABA: short-acting beta agonists. The items in blue correspond to the best control performance for each item, and those in red the worst
control performance. NA: data not available. The data for the AIA, AIRE, AIRIAP, AIRJ and AIRCEE surveys are taken from Rabe et al.,
2004 19.
Fig. 2. Hospitalisations and emergency department visits in the different AIR studies.
(20.6%), although worse than in the AIRGNE (52%) and AIRSA
(32.4%) surveys. Nonetheless asthma control as measured
with the ACT, is still largely unsatisfactory in all these
countries.
With respect to perceived control, less than ten percent
of subjects in the AMOA study considered their asthma to
be ‘poorly controlled’ and over ﬁfty percent considered
it ‘well controlled’ 21. This optimistic vision was even
shared by individuals who reported daily asthma symptoms.
Comparable ﬁndings were reported from the AIRET study
in Turkey 22, where 45% of respondents considered their
asthma to be well controlled, in spite of the fact that
only 1.5% fulﬁlled all ﬁve GINA control criteria. Similarly, in
Canada (AIRC study), 49% of subjects considered themselves
to be very well controlled and 42% considered it adequately
controlled 16. In the AIRMAG study, 31.0% considered their
asthma to be uncontrolled and although 71.3% were classi-
ﬁed as uncontrolled using the ACT. These ﬁndings all suggest
that patient perceptions of asthma control do not match the
strict deﬁnition of control set out in the GINA recommen-
dations, or that expectations or knowledge of the potential
beneﬁts of treatment are low. Indeed, a dedicated study on
perceptions of asthma control performed in general prac-
tice in France (ER’Asthme) 71,72 has revealed that patients
with asthma systematically over-estimate the quality of
their asthma control compared to their family physicians. In
this study, only 8% of adult patients considered their asthma
control to be poor, whereas their physicians considered
control to be unacceptable in 72% of patients 71.
Several large clinical studies, notably the GOAL study 73,
have shown that using recommended asthma treatments,
namely inhaled corticosteroids (ICS) in monotherapy or in
combination with long-acting beta-agonists (LABA), in a
dynamic ‘treat to target’ therapy regimen can achieve
asthma control in many patients, although it should be
recognised that these studies generally excluded the most
severe patients.
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Table 4. Perceptions about asthma and its treatment in the AIRMAG sample (adults with asthma)
Algeria (N = 154) Morocco (N = 236) Tunisia (N = 234) Total (N = 624)
Aware that asthma is caused by inﬂammation of the airways 14 (9.8%) 59 (26.1%) 31 (14.0%) 104 (17.6%)
Considers asthma to be a psychological problem 117 (76.9%) 131 (56.9%) 148 (63.8%) 396 (64.5%)
Aware that underlying cause can be treated 29 (23.0%) 59 (35.5%) 62 (32.6%) 150 (31.1%)
Aware of treatment guidelines 18 (12.7%) 54 (23.8%) 26 (11.9%) 98 (16.7%)
Knows about ICS 42 (29.4%) 87 (39.4%) 45 (20.6%) 174 (29.9%)
Considers that it is possible to live normally with asthma 125 (82.3%) 1645 (71.6%) 148 (63.8%) 437 (71.3%)
Resigned about living with asthma 105 (68.6%) 168 (72.7%) 170 (72.9%) 443 (71.8%)
Considers that asthma restricts activities 134 (87.0%) 162 (70.2%) 172 (73.9%) 468 (75.8%)
Has difﬁculty accepting their disease 75 (49.4%) 115 (50.0%) 114 (48.9%) 304 (49.4%)
Fig. 3. Reported inhaled corticosteroid use in the different AIR surveys.
However, it is clear from the AIRMAG study, as was the
case in previous AIR studies, that most individuals with
asthma are not informed on what can be achieved with
adequate treatment and, as a result, have low expectations
of treatments and are prepared to accept a sub-optimal
quality of life (Table 4). Less than one respondent in ﬁve
was aware that asthma was caused by inﬂammation of the
airways, and around two-thirds considered that it was a psy-
chological problem. Less than a third were aware that the
underlying disease process could be treated or had heard of
ICS. An even lower proportion of respondents were aware of
treatment guidelines. Although three-quarters thought that
it was possible to live normally with asthma, a similar pro-
portion considered that their asthma restricted their activi-
ties and claimed to be resigned to living with their asthma,
which implies that they have a different perspective on
what ‘living normally’ means to people without asthma.
Better education of patients with asthma on what can be
expected from treatment in terms of reduction in symptoms
and quality of life is clearly needed. If patients understood
clearly that their treatment could be adjusted if adequate
symptom control is not achieved, then they would be more
likely to consult their physician in such cases, rather than
waiting for a serious exacerbation to occur before they call
a doctor or get taken to hospital, which is what happens at
the moment.
Asthma treatment
Concerning treatment, 26.1% of adults and 29.1% of children
in the AIRMAG study were receiving ICS, either alone or
in combination with LABA. Compared to the previous AIR
studies, these treatment rates are rather high (Fig. 3). In
previous AIR surveys, the highest rate of ICS use was 39%,
reported in the AIRSA study in Saudi Arabia performed in
2007 24. It should however be borne in mind that the earliest
AIR surveys were performed a decade previously to AIRMAG,
and it is legitimate to believe that ICS use would have
increased across the intervening period. Indeed, between
the two AIRJ surveys conducted in Japan in 2000 and 2005,
ICS use in adults increased by ﬁfty percent (from 12% to
18%). Similarly, in a survey of children consulting for asthma
in France performed in 2005 (ELIOS study 72), 71.2% were
receiving an ICS. This is fourfold higher than the rate of use
reported in French children in the AIRE study performed in
1999 (19.6%).
Nonetheless, no information was available in any of the
AIR studies on the dose of ICS used, so it is impossible
to know whether these were appropriate to obtain and
maintain a good control. Systematic under-dosing of ICS
has been reported previously in a survey of several
developing countries, including Algeria 74. Another issue
concerns persistence with ICS treatment. Although nine out
of ten respondents reported using ICS at least once a day to
prevent asthma symptoms, it is likely that ‘drug holidays’
or treatment lapses during periods of good asthma control
were not infrequent. Indeed, prescription claims data
collected in North America 75 81 and Europe 82 84 indicate
that prescriptions for ICS are frequently not reﬁlled, that
compliance to treatment is poor and that use of medication
is irregular. In France, less than one-third of new ICS users
receive more than one repeat prescription 83, and one-year
treatment persistence rates are lower than ten percent in
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Table 5. Reasons given for non-adherence to asthma treatments in adults of the AIRMAG population
Algeria (N = 154) Morocco (N = 236) Tunisia (N = 234) Total (N = 624)
Lack of understanding of the importance of treatment 105 (77.2%) 178 (84.0%) 144 (66.4%) 427 (75.6%)
Cost of treatment too high 111 (82.8%) 175 (82.9%) 148 (67.9%) 434 (77.1%)
Absence of symptoms 86 (65.2%) 130 (62.2%) 122 (56.0%) 338 (60.5%)
Concerns about long-term medication use 84 (66.7%) 127 (62.6%) 118 (54.6%) 329 (60.4%)
Concerns about side-effects 84 (65.6%) 125 (61.0%) 105 (48.4%) 314 (57.1%)
Belief that treatment efﬁcacy is lost over time 85 (66.4%) 123 (59.7%) 120 (55.0%) 328 (59.4%)
Absence of immediate effect of medication 81 (63.3%) 120 (58.8%) 112 (51.4%) 313 (56.9%)
Table 6. Management plan for asthma proposed by the Global Initiative for Asthma (GINA) 87
Six-Point Management Plan for asthma (GINA)
1. Educate patients to develop a partnership in asthma management
2. Assess and monitor asthma severity with symptom reports and measures of lung function as much as possible
3. Avoid exposure to risk factors
4. Establish medication plans for chronic management in children and adults
5. Establish individual plans for managing exacerbations
6. Provide regular follow-up care
both France and North America 77,78,83. Poor adherence to
asthma controller medication has been shown to be associ-
ated with loss of control and poor disease outcome 81,85.
Moreover, in the AIRMAG study (in which adherence
was not determined), a majority of adults with asthma
interviewed reported that cost of medication, resolution of
symptoms, concerns about long term treatment and lack of
understanding of treatment goals were important factors in
non-adherence to treatment (Table 5).
Access to medication is clearly an issue in developing
countries 86, such as the Maghreb, although as we have
seen, reported use of ICS in the AIRMAG survey does not
compare particularly unfavourably with other regions of the
world, and is indeed higher than reported treatment rates
in other developing countries in Asia and Latin America.
In the World Health Organization classiﬁcation of access
to essential drugs, Algeria and Tunisia are considered
to provide access for 81 95% of their population and
Morocco access for 50 80% 1, although it should be noted
that ICS use in the AIRMAG survey was actually higher
in Morocco than in the other two countries. Apart from
intrinsic drug costs, insurance reimbursement, insurance
coverage, the presence of ICS on lists of essential drugs in
national pharmacies, public health priorities, distribution
infrastructure, the availability of generics, and the relative
weights of the private and public healthcare sectors are all
factors that inﬂuence access to optimal asthma care 1,86.
Asthma management
The 2002 GINA guidelines 87 proposed a six-point plan to
improve the management of asthma (Table 6). In the
2008 revision 88, the number of points was consolidated to
four, but the basic principles remain unchanged. The ﬁrst
point relates to patient education, and as we have seen
above, there is a clear need for better information to be
provided to patients with asthma in the Maghreb, in order to
improve the accuracy of their perceptions of their disease
and its treatment, to make their treatment expectations
more realistic, to help them understand the importance
of treatment adherence and to empower them to take an
active part in the management of their asthma. Most of the
individuals with asthma who took part in the AIRMAG study
(540/624; 93.6%) considered that being better educated
about asthma was very important for them, which suggests
that a patient-directed information campaign could be
effective.
With regard to risk factors, active or passive smoking
is the only one that has been investigated in the
AIRMAG survey. Although rates of active smoking are
relatively low (4% in Algeria and Morocco, and 12% in
Tunisia) compared to the general population in these
countries, and also compared to Europeans with asthma
identiﬁed in the AIRE study ten years previously, of
whom 17.5% were active smokers 17. On the other hand,
passive exposure to tobacco smoke was very common in
AIRMAG respondents, particularly in Tunisia where over
half of adults and children with asthma had at least
one smoker in the family, compared with a proportion
of smokers in the general population of 34.8% 89. Public
health campaigns emphasising the harmfulness of smoking
for other members of the household should be considered
in the Maghreb.
The other elements of the GINA management plan relate
to proactive follow-up of asthma control. For all of these
points, care standards as reported in the AIRMAG survey
leave much to be desired (Table 7). Follow-up consultations
were only programmed for one-third of adults with asthma.
Only one in ﬁve received a written asthma management
plan, one in six had undergone a lung function test, one
in ten received a standardised asthma evaluation and only
in twenty possessed a peak ﬂow meter for use at home.
It is very important that physicians should recognise the
necessity of programming regular follow-up visits at which
asthma control should be evaluated systematically and lung
function measured periodically.
For all these points, physician education programmes
could be designed by asthma specialists in the Maghreb with
the goal of making physicians aware of the fundamental
importance of monitoring the asthma of their patients
systematically and adapting their controller treatment
according to the evolution of symptoms. Such a relatively
inexpensive measure could have a profound impact on
achieving better asthma control.
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Table 7. Management of asthma in adults with asthma in the AIRMAG survey
Algeria (N = 154) Morocco (N = 236) Tunisia (N = 234) Total (N = 624)
Lung function testing 33 (23.1%) 29 (13.1%) 36 (15.9%) 98 (16.6%)
Peak ﬂow meter use
During consultations
At home
36 (25.0%)
2 (5.4%)
103 (46.4%)
2 (2.2%)
54 (23.6%)
5 (7.0%)
193 (32.4%)
9 (4.5%)
Drafting of an action plan 25 (17.6%) 37 (16.7%) 52 (22.9%) 114 (19.3%)
Standardised evaluation form 14 (9. 7%) 22 (9.9%) 20 (8.8%) 56 (9.4%)
Programmed follow-up visits 48 (34.8%) 75 (35.2%) 85 (37.8%) 208 (36.1%)
Treatment rates, both for asthma controller medication
(26%) and for relief medication for the management of
exacerbations (57%), were low, and illustrate the barriers to
access to optimal care that exist throughout the developing
world 86,90. As pointed out by the GINA ‘Burden of asthma’
report 1, extrapolation of models of, and strategies for,
healthcare provision from industrialised countries to the
developing world may be very misleading. In this respect,
studies such as AIRMAG play an important role in generating
reliable data on asthma and its management in participating
countries, which can be used to plan national asthma
policies that are appropriate and adapted for the Maghreb.
Conclusions
In conclusion, the picture of asthma revealed by the AIRMAG
survey reveals a moderate prevalence of asthma in the
Maghreb countries. The reason why asthma prevalence is
lower than in Western Europe may relate to dietary habits,
contact with animals or infection with Mycobacterium
tuberculosis. However, since North African society is
becoming increasingly ‘westernised’, it is possible that
exposure to risk factors and protective factors may be
shifting in response to changes in lifestyle and living
standards. For this reason, it would be most interesting to
reiterate the AIRMAG study in ﬁve or ten years in order to
track such developments, and possibly link any changes seen
with identiﬁed environmental factors.
As observed in other developing regions of the world,
the burden of asthma is relatively high and levels of
control inadequate. The relatively poor asthma control
observed in the Maghreb compared to other regions
of the world seems to be explained not so much by
insufﬁcient access to controller treatments (although this
could certainly be improved), but by the fact that asthma
symptoms and treatments are not monitored systematically.
Education measures directed at the patient, to improve
patient understanding of disease and treatment, to reset
appropriate patient expectations and to involve patients
actively in the management of their asthma, together with
programmes directed at the physician to ensure systematic
monitoring and the use of a ’treat to target’ approach to
therapy, as recommended in the GINA guidelines, could do
much to increase quality of life and minimise restrictions
on activities in patients with asthma in the Maghreb.
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